Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Bone marrow biopsy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    887 result(s) found for: Bone marrow biopsy. Displaying page 7 of 45.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2018-001246-34 Sponsor Protocol Number: JCAR017-BCM-004 Start Date*: 2021-11-15
    Sponsor Name:Celgene Corporation
    Full Title: A phase 1 / 2, open-label, single arm, multicohort, multicenter trial to evaluate the safety and efficacy of JCAR017 in pediatric subjects with relapsed/refractory B-ALL and B-NHL (TRANSCEND PEDALL)
    Medical condition: Relapsed or refractory (r/r) CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) and B-Cell Non-Hodgkin Lymphoma (B-NHL).
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10029593 Non-Hodgkin's lymphoma NOS LLT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    21.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) BE (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004936-36 Sponsor Protocol Number: CLL13 Start Date*: 2016-11-08
    Sponsor Name:University of Cologne
    Full Title: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus ve-netoclax (RVe) versus obinutuzumab (GA101) plus venetoclax (GVe) ve...
    Medical condition: fit patients with previously untreated CLL without del(17p) or TP53 mutation
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) DE (Completed) AT (Completed) FI (Completed) BE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2012-003392-18 Sponsor Protocol Number: FIL_RENOIR12 Start Date*: 2014-04-17
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A randomized phase III multicenter trial assessing efficacy and toxicity of a combination of Rituximab and Lenalidomide (R2) vs Rituximab alone as maintenance after chemoimmunotherapy with Rituxim...
    Medical condition: Maintenance following R-chemotherapy (Rituximab-Bendamustine) of patients with follicular lymphoma in first or second relapse or progression and not eligible for autologous stem cell transplantatio...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-004008-20 Sponsor Protocol Number: IPI-145-06 Start Date*: 2014-01-13
    Sponsor Name:Verastem, Inc.
    Full Title: A Phase 2 Study of IPI-145 in Subjects with Refractory Indolent Non-Hodgkin Lymphoma.
    Medical condition: Refractory Indolent Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10029627 Non-Hodgkin's lymphoma unspecified histology intermediate grade refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) HU (Completed) CZ (Completed) ES (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-005339-42 Sponsor Protocol Number: N16HPV Start Date*: 2016-08-30
    Sponsor Name:NKI-AVL
    Full Title: Safety, immunogenicity and clinical response of sig-HELP-E6SH/E7SH-kdel, injected in the epidermis by DNA tattoo, in HPV16-positive vulvar intraepithelial neoplasia: a phase I/II study
    Medical condition: HPV16+ usual type vulvar intraepithelial neoplasia (uVIN)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002851-33 Sponsor Protocol Number: 12197 Start Date*: 2006-08-18
    Sponsor Name:Univ. Prof. Dr. Manuela Schmidinger
    Full Title: Sorafenib and Bevacizumab as first- line treatment in patients with advanced renal cell carcinoma
    Medical condition: Patients with advanced renal cell carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005738-11 Sponsor Protocol Number: CRAD001C2445 Start Date*: 2006-08-23
    Sponsor Name:Unidad integral de investigación en oncologia
    Full Title: Phase II Study of Single Agent RAD001 in Patients with Colon Cancer and Activating Mutations in the PI3KCA gene.
    Medical condition: Colon Cancer
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023032-17 Sponsor Protocol Number: CRAD001K24133 Start Date*: 2011-04-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors
    Medical condition: The study will evaluate the safety of everolimus in patients with advanced neuroendocrine tumors of gastrointestinal, lung or pancreatic origin.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) SE (Prematurely Ended) GR (Completed) BE (Completed) DK (Completed) PT (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000813-36 Sponsor Protocol Number: HHT-CML/INTL/04.2 Start Date*: 2005-10-14
    Sponsor Name:STRAGEN France [...]
    1. STRAGEN France
    2. ChemGenex Pharmaceuticals Ltd.
    Full Title: A phase II, multicentre, single-arm, open-label study of subcutaneous homoharringtonine (HHT) alone in patients with accelerated phase chronic myeloid leukemia (CML) who are refractory to, or have ...
    Medical condition: Accelerated phase Chronic Myeloid Leukaemia (CML).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001224-36 Sponsor Protocol Number: A4021010 Start Date*: 2005-06-10
    Sponsor Name:Pfizer Inc. - Research & Development
    Full Title: Phase 1, Open Label, Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-751,871 in Patients with Advanced Solid Tumours
    Medical condition: Advanced Solid Tumours
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004119-36 Sponsor Protocol Number: METOXY-LACC Start Date*: 2019-11-04
    Sponsor Name:Oslo University Hospital
    Full Title: Altered tumor oxygenation by Metformin, a potential step in overcoming radiotherapy resistance in locally advanced cervical cancer.
    Medical condition: Locally advanced cervical cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006881-40 Sponsor Protocol Number: AURA-6202-005 Start Date*: 2007-01-31
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy
    Medical condition: Treatment of Chronic Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009013 Chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004583-26 Sponsor Protocol Number: LV2020-001 Start Date*: 2022-03-08
    Sponsor Name:LAVA Therapeutics N.V.
    Full Title: A Phase 1 and 2a open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and antitumor activity of LAVA-051 in patients with relapsed or refractory...
    Medical condition: Relapsed/refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM), or acute myeloid leukemia (AML)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Prematurely Ended) ES (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002249-13 Sponsor Protocol Number: 3125001 Start Date*: 2019-02-04
    Sponsor Name:Orion Corporation Orion Pharma
    Full Title: SAFETY AND PHARMACOKINETICS OF ODM-209 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BRE...
    Medical condition: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER OR ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE ADVANCED BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003985-40 Sponsor Protocol Number: CZOL446G2422 Start Date*: 2006-01-09
    Sponsor Name:Department of Internal Medicine, University Hospital Gasthuisberg
    Full Title: A prospective multicentre phase II trial of zoledronic acid in patients with myelofibrosis with myeloid metaplasia (MMM)
    Medical condition: myelofibrosis with myeloid metaplasia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-004360-26 Sponsor Protocol Number: CLL16 Start Date*: 2021-08-24
    Sponsor Name:German CLL Study Group (University of Cologne)
    Full Title: A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZUMAB AND VENETOCLAX (GVE) IN PREVIOUSLY UNTREATED PATIENTS...
    Medical condition: Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004836-39 Sponsor Protocol Number: Initial-1 Start Date*: 2017-11-01
    Sponsor Name: Goethe Universität
    Full Title: An open label phase II study to evaluate the efficacy and safety of Inotuzumab Ozogamicin for Induction Therapy followed by a conventional chemotherapy based consolidation and maintenance therapy I...
    Medical condition: Acute lymphoblastic leukemia, Philadelphia-chromosome and BCR-ABL negative disease, patient aged 56 years or older
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005173-28 Sponsor Protocol Number: BLU-263-1201 Start Date*: 2021-09-06
    Sponsor Name:Blueprint Medicines Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis
    Medical condition: Indolent Systemic Mastocytosis (ISM) and monoclonal Mast Cell Activation Syndrome (mMCAS)
    Disease: Version SOC Term Classification Code Term Level
    27.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10056452 Indolent systemic mastocytosis PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) ES (Trial now transitioned) AT (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002830-36 Sponsor Protocol Number: EORTC 06011 Start Date*: 2005-11-09
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Intravenous low-dose decitabine versus supportive care in elderly patients with primary Myelodysplastic Syndrome (MDS) (>10 % blasts or high-risk cytogenetics), secondary MDS or Chronic Myelomonocy...
    Medical condition: The myelodysplastic syndrome (MDS) comprises a heterogenous group of hematopoietic stem cell disorders. - quantitative and morphologic abnormalities of bone marrow and peripheral blood cells - c...
    Disease: Version SOC Term Classification Code Term Level
    8.0 10028536 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-001086-41 Sponsor Protocol Number: UKM10_0014 Start Date*: 2012-02-28
    Sponsor Name:University Hospital of Muenster
    Full Title: A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an in...
    Medical condition: untreated acute myeloid leukemia patients unfit for an intensive treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jul 16 13:16:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA